HALO vs. MNTA, CBPO, TWST, NVAX, IOVA, ALNY, BMRN, NBIX, INCY, and UTHR
Should you be buying Halozyme Therapeutics stock or one of its competitors? The main competitors of Halozyme Therapeutics include Momenta Pharmaceuticals (MNTA), China Biologic Products (CBPO), Twist Bioscience (TWST), Novavax (NVAX), Iovance Biotherapeutics (IOVA), Alnylam Pharmaceuticals (ALNY), BioMarin Pharmaceutical (BMRN), Neurocrine Biosciences (NBIX), Incyte (INCY), and United Therapeutics (UTHR). These companies are all part of the "medical" sector.
Halozyme Therapeutics (NASDAQ:HALO) and Momenta Pharmaceuticals (NASDAQ:MNTA) are both mid-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their community ranking, risk, profitability, dividends, institutional ownership, valuation, analyst recommendations, earnings and media sentiment.
Halozyme Therapeutics presently has a consensus target price of $54.13, indicating a potential upside of 5.80%. Given Halozyme Therapeutics' higher probable upside, equities research analysts clearly believe Halozyme Therapeutics is more favorable than Momenta Pharmaceuticals.
Halozyme Therapeutics has higher revenue and earnings than Momenta Pharmaceuticals. Momenta Pharmaceuticals is trading at a lower price-to-earnings ratio than Halozyme Therapeutics, indicating that it is currently the more affordable of the two stocks.
Halozyme Therapeutics has a beta of 1.28, indicating that its stock price is 28% more volatile than the S&P 500. Comparatively, Momenta Pharmaceuticals has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500.
Halozyme Therapeutics has a net margin of 36.94% compared to Momenta Pharmaceuticals' net margin of -757.61%. Halozyme Therapeutics' return on equity of 225.71% beat Momenta Pharmaceuticals' return on equity.
In the previous week, Halozyme Therapeutics had 25 more articles in the media than Momenta Pharmaceuticals. MarketBeat recorded 25 mentions for Halozyme Therapeutics and 0 mentions for Momenta Pharmaceuticals. Halozyme Therapeutics' average media sentiment score of 0.51 beat Momenta Pharmaceuticals' score of 0.00 indicating that Halozyme Therapeutics is being referred to more favorably in the media.
Momenta Pharmaceuticals received 63 more outperform votes than Halozyme Therapeutics when rated by MarketBeat users. However, 69.18% of users gave Halozyme Therapeutics an outperform vote while only 66.59% of users gave Momenta Pharmaceuticals an outperform vote.
97.8% of Halozyme Therapeutics shares are owned by institutional investors. 2.7% of Halozyme Therapeutics shares are owned by company insiders. Comparatively, 3.4% of Momenta Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.
Summary
Halozyme Therapeutics beats Momenta Pharmaceuticals on 13 of the 17 factors compared between the two stocks.
Get Halozyme Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for HALO and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding HALO and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Halozyme Therapeutics Competitors List
Related Companies and Tools
